Poor
Needs Revision
Patient Risk:
Moderate
Summary
Only the mechanism-related and boxed-warning-related items are plausibly label-linked, but key claims about indication timing, manufacturers, and general descriptions (e.g., “multimodal,” “MOA not fully understood,” and “inhibition of serotonin reuptake”) are not supported by the supplied label excerpts. Several claims are not evaluable against the provided label text.
Category Scores
Accurate Statements
The active ingredient in Trintellix is vortioxetine.
Supported by the provided context that TRINTELLIX is (vortioxetine). No contrary label excerpt was provided.
Trintellix is indicated for the treatment of major depressive disorder (MDD) in adults.
Indication alignment is asserted in the user-provided label context (“adult MDD indication”), though the actual indication text was not included in the excerpt.
Unsupported Statements
Trintellix was first approved by the FDA in October 2013.
No approval-date information is present in the supplied label excerpts.
Following its FDA approval in October 2013, Trintellix became available for prescription and dispensing by pharmacies shortly thereafter.
No post-approval availability/dispensing timing information is present in the supplied label excerpts.
Trintellix is manufactured by Takeda Pharmaceuticals and Lundbeck.
No manufacturer information is present in the supplied label excerpts.
Vortioxetine is a multimodal antidepressant.
No description of “multimodal” pharmacology is present in the supplied label excerpts.
The exact mechanism of action of vortioxetine is not fully understood.
No mechanism-of-action completeness/uncertainty statement is present in the supplied label excerpts.
Vortioxetine is believed to involve inhibition of serotonin reuptake and modulation of various serotonin receptors.
No mechanism-of-action description (serotonin reuptake inhibition or receptor modulation) is present in the supplied label excerpts.
Contradictions
Low
AI Statement
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS (as referenced/claimed to be supported).
Label Reference
Supplied label excerpts support the existence of the boxed warning and related monitoring/counseling; however, the AI response content provided to evaluate includes no explicit boxed warning text beyond the claim scaffold. This is not a direct contradiction of the label wording, but the evaluation cannot confirm exact alignment of the AI’s warning statement text to the provided label text.
Important Omissions
The AI response did not accurately reproduce or specifically detail the boxed warning language from the supplied label excerpt (e.g., that antidepressants increase risk in pediatric and young adult patients in short-term studies, and that TRINTELLIX is not approved for pediatric use).
Importance:
Moderate
No explicit monitoring instructions from Section 5.1/Section 17 were quoted or paraphrased in the AI response content shown (e.g., monitor all antidepressant-treated patients, especially early and with dose changes; advise patients/caregivers to report emergence of suicidal ideation/behavior).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI response’s warning-related content was not validated against the supplied boxed-warning wording/monitoring/counseling instructions; several other claims were unsupported. This reduces reliability when communicating safety-critical label information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple claims (approval date, availability timing, manufacturer, and mechanism descriptors) are not supported by the supplied label excerpts, and the warning content is not explicitly aligned to the provided boxed warning/monitoring/counseling text.
Suggested Improvement
Limit claims to information explicitly supported by the provided label excerpts (e.g., vortioxetine as active ingredient; adult MDD indication as stated in provided context; boxed warning/Section 5.1/8.4/17 monitoring and counseling instructions). Avoid manufacturer, approval-date, and mechanism-of-action specifics unless the corresponding label text is provided.